Best Probiotic for Men Evidence-graded, strain by strain

Probiotic safety, and who should not take them

At population level the pooled safety data are genuinely reassuring, and that must be reported as such. Cochrane 2025: adverse events RR 0.86 (0.72–1.01) — no difference either way. Across 55 IBS trials and 7,000+ patients, risk of any adverse event was not significantly raised. AHRQ Evidence Report No. 200: overall adverse events RR 1.00 (95% CI 0.93–1.07), p=0.999; serious adverse events RR 1.06 (0.97–1.16), p=0.201.

, Independent analyst Last verified Disclosures

Both halves of the safety picture are here, in the order they were written: the reassuring pooled estimates first, then what the trials behind them did and did not monitor for.

Are probiotics safe?

For a generally healthy adult, the pooled data show no difference in adverse events (RR 0.86, 0.72–1.01; RR 1.00, 0.93–1.07). But most trials did not monitor for harms properly — 80% of 384 RCTs gave no serious-adverse-event count per group. And there are specific groups who should not take them without supervision: see the safety section above.

That list is further down this page, in the passage that begins "Who should not take these without medical supervision".

Safety: the honest both-halves version

And the literature that produced those nulls did not systematically look. AHRQ searched 12 databases and included 622 studies, of which 235 (37.8%) made only nonspecific safety statements, concluding that "Interventions and adverse events were poorly documented" and "long-term effects are largely unknown." Across 384 RCTs: 106 (28%) reported no harms-related data; 142 (37%) no safety results; 309 (80%) gave no serious-adverse-event count per group; 375 (98%) gave no adverse-event definition (PMID 30014150). "No signal in trials that did not monitor for the signal" is not the same as "safe." Both halves belong in the same paragraph.

The canonical harm case, with its scope attached. PROPATRIA: 298 randomised, predicted severe acute pancreatitis, multispecies probiotic enterally twice daily for 28 days. Primary composite not met (RR 1.06, 0.75–1.51). Mortality 24/152 (16%) versus 9/144 (6%), RR 2.53 (1.22–5.25). Bowel ischaemia: nine cases in the probiotic group, eight fatal, versus none in placebo, p=0.004. The trialists: "Probiotic prophylaxis should therefore not be administered in this category of patients" (PMID 18279948). This is not generalisable to a healthy man taking a capsule — and the record carries both an Expression of Concern and an Erratum, which we disclose rather than omit.

Product-derived bloodstream infection is documented at strain level, in intensive care. Two ICU patients developed Lacticaseibacillus rhamnosus bacteraemia whose PFGE patterns were identical to the commercial probiotic administered to them (PMID 36145409). Across 22,174 ICU patients over 5.5 years, 522 of whom received an LGG-containing probiotic: Lactobacillus bacteraemia 6/522 (1.1%) versus 2/21,652, P = 4.8 × 10⁻⁹, with blood isolates "phylogenetically inseparable" from the product (PMID 31700189). The authors' own counterweight belongs with it: an additional 10 cases among ~93,000 non-ICU patients, none of the 10 on a probiotic. Population-level context runs the other way too — lactobacilli account for 0.02% of all blood cultures, at an average incidence of 0.3 cases per 100,000 inhabitants per year, with no trend suggesting an increase despite rising LGG use since 1990 (PMID 12410474).

S. boulardii fungaemia is catheter-associated and repeatedly documented, including seven cases in a single 12-bed ICU over 28 months, three cases in roommates of treated patients, and a population-scale estimate of 18 fungaemias among 16,404 recipients (0.11%), ICU OR 6.55 (2.28–18.87) — with the authors' honest conclusion that the risk "does not appear greater than the risk of any hospital-acquired bloodstream infection." The EMA extended the contraindication to critically ill and immunocompromised patients in November 2017, on top of a pre-existing contraindication with central venous catheters, after 61 cumulative fungaemia cases and 10 fatal cases where causality could not be excluded.

The resistome finding, in its correct form. In healthy volunteers, probiotics reduced antibiotic-resistance genes "exclusively in the gut of colonization-permissive individuals." Post-antibiotics they "further exacerbated resistome expansion in the GI mucosa by supporting the bloom of strains carrying vancomycin resistance genes but not resistance genes encoded by the probiotic strains", with disruption persisting "more than three months after supplementation ceases" (PMID 34226711). The risk is not the probiotic's own genes; it is which of your residents bloom. No human demonstration of resistance-gene transfer from an ingested commercial probiotic to a human pathogen exists; the demonstration is in mice.

One male-specific adverse signal exists, in an animal model, and belongs at exactly that strength: "The greatest inflammatory response was seen in male, Western-diet-exposed, and probiotic-treated rats" (PMID 33027912).

Who should not take these without medical supervision: critically ill or ICU patients · people with predicted severe acute pancreatitis · preterm and very-low-birth-weight infants outside a supervised protocol · anyone with a central venous catheter · immunocompromised or immunosuppressed patients · people with structural heart disease, valvulopathy or prosthetic valves. NCCIH puts it plainly: "The risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems", and "Few studies have looked at the safety of probiotics in detail." ISAPP agrees: "If you're generally healthy, probiotics are likely to be safe. But if you have a serious medical condition… then you should talk to your doctor."

Two more specific exclusions. An undesignated Enterococcus faecalis on a label cannot be screened by the buyer for cytolysin, aggregation substance or transferable vancomycin resistance — and EFSA concluded in 2007 that enterococci do not meet the standard for Qualified Presumption of Safety (PMID 32036912). And Debaryomyces hansenii, present on one men's product's label, is enriched in Crohn's intestinal tissue and impairs colonic healing in mice with Koch's postulates fulfilled (PMID 33707263, Science 2021) — a reasonable exclusion for readers with IBD or Crohn's, not a consumer alarm and not an adverse-event claim about that product.

If you are on immune checkpoint inhibitors, raise probiotic use with your oncologist rather than self-supplementing. The human data are null (progression-free survival HR 1.30, 95% CI 0.82–2.07, p=0.27, n=158), the much-quoted "loss of the fibre benefit" rests on a four-way subgroup whose key cell holds about twelve patients, and the demonstrated impairment of anti-PD-1 response is in mice. The question is genuinely open, not a demonstrated harm.

And the largest real-world harm in this category is not pharmacological. It is a man treating a urological symptom with a supplement while a diagnosis waits.

The strains named above, and the labels in this audit that print them

Every row below is a line on a printed supplement panel, read off that product’s own teardown. A panel printing a designator is a fact about the panel. It is not evidence that the product was tested, that it delivers the amount that was studied, or that the strain does anything — several of the paragraphs above say in terms that it does not, and the dose is unknowable wherever the panel gives no per-organism quantity.

L. rhamnosus GG (ATCC 53103)
Saccharomyces boulardii
Enterococcus faecalis, undesignated

Not printed on any panel this audit has transcribed.

Debaryomyces hansenii

Scope, stated because an absence here is a published claim: this searches the organism slots transcribed from 156 of the 166 labels in the audit. A panel that is not fully transcribed can hide a line, so “not printed on any panel this audit has transcribed” is exactly that, and never “not sold anywhere”. Each product links to its own label audit, where the panel, the designator resolution and the arithmetic are set out in full.

Read next

This is the section published on the home page under #safety, relocated unchanged.